AG01 is a monoclonal antibody targeting the anti-granular protein precursor (GP88). It inhibits the proliferation and migration of triple-negative breast cancer (TNBC) cells, reducing the expression of phosphorylated protein kinases such as p-Src, p-AKT, and p-ERK, as well as oncogenic proteins like Axl, c-MET, HIF-1α, and VEGF. In TNBC xenograft mouse models, AG01 suppresses tumor growth and the expression of Ki67 in vivo. AG01 is useful for research involving cancers like TNBC.

AG01, in concentrations ranging from 0 to 300 µg/mL over 48 to 72 hours, is capable of inhibiting the proliferation of MDA-MB-231 and HS578-T cells, resulting in a reduction in the number of Ki67 positive nuclei. At concentrations of 0 to 100 µg/mL over 5 hours, AG01 can suppress the migration and invasion of these cells. Additionally, AG01 at 100 µg/mL from 24 to 72 hours can decrease the phosphorylation states of AKt, Src, and Erk1/2 in MDA-MB-231 and HS578-T cells. Furthermore, AG01 at 100 µg/mL over 24 to 72 hours can lower the expression levels of Axl, c-MET, ICAM-1, MMP-2, SNAIL, HIF-1α, VEGF, endogenous precursor protein, SPARC, cell adhesion, and migration protein-fibronectin in these cell lines.

AG01 (10 mg/kg, intraperitoneally injected, twice a week for 40 days) effectively inhibits tumor growth and Ki67 expression in an MDA-MB-231 xenograft nude mouse model.